Pierre Fabre Medicament
10 products tracked · names used in filings: Pierre Fabre Medicament
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Milnacipran Pierre Fabre Medicament milnacipran | Refused | |
| 🇪🇺 | Impulsor milnacipran | Refused | |
| 🇪🇺 | Obgemsa vibegron | Authorised | 2024-06-27 |
| 🇪🇺 | Ebvallo tabelecleucel | Authorised | 2022-12-16 |
| 🇪🇺 | Mektovi binimetinib | Authorised | 2018-09-20 |
| 🇪🇺 | Braftovi encorafenib | Authorised | 2018-09-19 |
| 🇪🇺 | Nerlynx neratinib | Authorised | 2018-08-31 |
| 🇪🇺 | Hemangiol propranolol | Authorised | 2014-04-23 |
| 🇪🇺 | Javlor vinflunine | Authorised | 2009-09-21 |
| 🇪🇺 | Busilvex busulfan | Withdrawn | 2003-07-09 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.